BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 8158458)

  • 1. Expression of p53 in oligodendrogliomas.
    Kros JM; Godschalk JJ; Krishnadath KK; Van Eden CG
    J Pathol; 1993 Dec; 171(4):285-90. PubMed ID: 8158458
    [TBL] [Abstract][Full Text] [Related]  

  • 2. p53 protein alterations in adult astrocytic tumors and oligodendrogliomas.
    Nayak A; Ralte AM; Sharma MC; Singh VP; Mahapatra AK; Mehta VS; Sarkar C
    Neurol India; 2004 Jun; 52(2):228-32. PubMed ID: 15269478
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of the proliferation-related antigen Ki-67 in oligodendrogliomas.
    Kros JM; Hop WC; Godschalk JJ; Krishnadath KK
    Cancer; 1996 Sep; 78(5):1107-13. PubMed ID: 8780550
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic relevance of TP53 mutations, p53 protein, Ki-67 index and conventional histological grading in oligodendrogliomas.
    Hagel C; Krog B; Laas R; Stavrou DK
    J Exp Clin Cancer Res; 1999 Sep; 18(3):305-9. PubMed ID: 10606174
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The expression of cell cycle regulatory proteins in oligodendroglial tumors.
    Kamiya M; Nakazato Y
    Clin Neuropathol; 2002; 21(2):52-65. PubMed ID: 12005253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of p53 protein has no independent prognostic value in breast cancer.
    Pietiläinen T; Lipponen P; Aaltomaa S; Eskelinen M; Kosma VM; Syrjänen K
    J Pathol; 1995 Nov; 177(3):225-32. PubMed ID: 8551383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms.
    Baas IO; Mulder JW; Offerhaus GJ; Vogelstein B; Hamilton SR
    J Pathol; 1994 Jan; 172(1):5-12. PubMed ID: 7931827
    [TBL] [Abstract][Full Text] [Related]  

  • 8. p53 overexpression and human papillomavirus infection in transitional cell carcinoma of the urinary bladder: correlation with histological parameters.
    Tenti P; Zappatore R; Romagnoli S; Civardi E; Giunta P; Scelsi R; Stella G; Carnevali L
    J Pathol; 1996 Jan; 178(1):65-70. PubMed ID: 8778319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survival analysis of presumptive prognostic markers among oligodendrogliomas.
    McLendon RE; Herndon JE; West B; Reardon D; Wiltshire R; Rasheed BK; Quinn J; Friedman HS; Friedman AH; Bigner DD
    Cancer; 2005 Oct; 104(8):1693-9. PubMed ID: 16116609
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Retinoblastoma and p53 tumour suppressor gene protein expression in carcinomas of the thyroid gland.
    Holm R; Nesland JM
    J Pathol; 1994 Mar; 172(3):267-72. PubMed ID: 8195930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of malignant features in oligodendroglial tumors.
    Saito A; Nakazato Y
    Clin Neuropathol; 1999; 18(2):61-73. PubMed ID: 10192700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [P53 protein expression and proliferative potential in non-recurrent and recurrent meningiomas].
    Miyagami M; Kanou T; Nakamura S
    No To Shinkei; 1996 Aug; 48(8):719-25. PubMed ID: 8797205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic alterations of the TP53 gene, p53 protein expression and HPV infection in primary cervical carcinomas.
    Helland A; Holm R; Kristensen G; Kaern J; Karlsen F; Trope C; Nesland JM; Børresen AL
    J Pathol; 1993 Oct; 171(2):105-14. PubMed ID: 8283348
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of apoptotic and proliferation markers in meningiomas.
    Konstantinidou AE; Pavlopoulos PM; Patsouris E; Kaklamanis L; Davaris P
    J Pathol; 1998 Nov; 186(3):325-30. PubMed ID: 10211124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. bcl-2 and p53 protein expression in follicular lymphoma.
    Cooper K; Haffajee Z
    J Pathol; 1997 Jul; 182(3):307-10. PubMed ID: 9349233
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic influence of p53 expression in gastric cancer.
    Müller W; Borchard F
    J Pathol; 1996 Mar; 178(3):255-8. PubMed ID: 8778328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Platelet-derived growth factor expression correlates with tumor grade and proliferative activity in human oligodendrogliomas.
    Majumdar K; Radotra BD; Vasishta RK; Pathak A
    Surg Neurol; 2009 Jul; 72(1):54-60. PubMed ID: 19559929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of p53, K-ras-2, and C-raf-1 in pulmonary neuroendocrine tumors. Correlation with histological subtype and clinical outcome.
    Przygodzki RM; Finkelstein SD; Langer JC; Swalsky PA; Fishback N; Bakker A; Guinee DG; Koss M; Travis WD
    Am J Pathol; 1996 May; 148(5):1531-41. PubMed ID: 8623922
    [TBL] [Abstract][Full Text] [Related]  

  • 19. p53 protein expression in human breast carcinoma: lack of prognostic potential for recurrence of the disease.
    Katoh A; Breier S; Stemmler N; Specht S; Blanock K; D'Amico F
    Anticancer Res; 1996; 16(3A):1301-4. PubMed ID: 8702254
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An immunohistochemical comparison between low-grade and high-grade ovarian serous carcinomas: significantly higher expression of p53, MIB1, BCL2, HER-2/neu, and C-KIT in high-grade neoplasms.
    O'Neill CJ; Deavers MT; Malpica A; Foster H; McCluggage WG
    Am J Surg Pathol; 2005 Aug; 29(8):1034-41. PubMed ID: 16006797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.